Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling Momentum Toward Addressing the Full Pathobiology of Alzheimer's

New data show greater tau reduction at higher doses but strongest clinical signal at lowest dose, raising key questions about optimal dosing in further trials, says the ADDF NEW YORK, July 14, 2026 /PRNewswire/ -- Today at the Alzheimer's Association International Conference (AAIC),...